PEPTONIC has started a collaboration with Clinartis in USA.
Clinartis is a consulting company within the clinical/regulatory area. They support us in the work with planning of a so called pre-IND meeting with FDA (Food and Drug Administration). This meeting will help us in designing the phase III study and will also guide us for the further development of Vagitocin. This meeting will be held on the 19.6.